Allogene co-founder and CEO Arie Belldegrun and Apellis CEO Cedric Francois said they contracted SARS-CoV-2, the virus that causes Covid-19. Both had been at a Cowen-sponsored healthcare investment conference, whose attendees included Biogen executives who subsequently tested positive.
The first FDA approval for a NASH drug, data on "off-the-shelf" CAR-T cells and a potential approval of a controversial drug for Alzheimer's disease are some of things in store for 2020.
Are you looking for a medical alert device that is elegant-looking and balances your independence and safety? Here are the best devices to choose from.
Allogeneic CAR-Ts could serve an important niche - particularly for patients who can't receive autologous CAR-Ts - but the earliness of the data makes conclusions tough to draw.
The company presented Phase I data from its study of allogeneic CAR-T UCART19, as well as preclinical data on a BCMA CAR-T for multiple myeloma.
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.